A Phase 2, Double-Blind Study of Ipilimumab Administered at 3mg/kg vs 10mg/kg in Adult Sujbects with Metastatic Chemotherapy-Naïve Castration Resistant Prostate Cancer Who are Asymptomatic or Minimally Symptomatic. The primary objective of this study is to estimate the radiographic progression-free survival of patients with chemotherapy-naïve castrate resistant prostate cancer patients randomized to ipilimumab 3mg/kg vs 10mg/kg

Principal Investigator: Jeanny Aragon-Ching, M.D.
Clinical Program: Urological Oncology Program
Primary Sponsor: Bristol-Myers Squibb, Inc.
Contact Info: 202-741-2981